TY - JOUR
T1 - The Molecular Registry of Pituitary Adenomas (REMAH): A bet of Spanish Endocrinology for the future of individualized medicine and translational research
AU - Luque, Raúl M.
AU - Ibáñez-Costa, Alejandro
AU - Sánchez-Tejada, Laura
AU - Rivero-Cortés, Esther
AU - Robledo, Mercedes
AU - Madrazo-Atutxa, Ainara
AU - Mora, Mireia
AU - Álvarez, Clara V.
AU - Lucas-Morante, Tomás
AU - Álvarez-Escolá, Cristina
AU - Fajardo, Carmen
AU - Castaño, Luis
AU - Gaztambide, Sonia
AU - Venegas-Moreno, Eva
AU - Soto-Moreno, Alfonso
AU - Gálvez, María Ángeles
AU - Salvador, Javier
AU - Valassi, Elena
AU - Webb, Susan M.
AU - Picó, Antonio
AU - Puig-Domingo, Manel
AU - Gilabert, Montserrat
AU - Bernabéu, Ignacio
AU - Marazuela, Mónica
AU - Leal-Cerro, Alfonso
AU - Castaño, Justo P.
PY - 2016/6/1
Y1 - 2016/6/1
N2 - © 2016 SEEN Pituitary adenomas are uncommon, difficult to diagnose tumors whose heterogeneity and low incidence complicate large-scale studies. The Molecular Registry of Pituitary Adenomas (REMAH) was promoted by the Andalusian Society of Endocrinology and Nutrition (SAEN) in 2008 as a cooperative clinical-basic multicenter strategy aimed at improving diagnosis and treatment of pituitary adenomas by combining clinical, pathological, and molecular information. In 2010, the Spanish Society of Endocrinology and Nutrition (SEEN) extended this project to national level and established 6 nodes with common protocols and methods for sample and clinical data collection, molecular analysis, and data recording in a common registry (www.remahnacional.com). The registry combines clinical data with molecular phenotyping of the resected pituitary adenoma using quantitative real-time PCR of expression of 26 genes: Pituitary hormones (GH-PRL-LH-FSH-PRL-ACTH-CGA), receptors (somatostatin, dopamine, GHRH, GnRH, CRH, arginine-vasopressin, ghrelin), other markers (Ki67, PTTG1), and control genes. Until 2015, molecular information has been collected from 704 adenomas, out of 1179 patients registered. This strategy allows for comparative and relational analysis between the molecular profile of the different types of adenoma and the clinical phenotype of patients, which may provide a better understanding of the condition and potentially help in treatment selection. The REMAH is therefore a unique multicenter, interdisciplinary network founded on a shared database that provides a far-reaching translational approach for management of pituitary adenomas, and paves the way for the conduct of combined clinical-basic innovative studies on large patient samples.
AB - © 2016 SEEN Pituitary adenomas are uncommon, difficult to diagnose tumors whose heterogeneity and low incidence complicate large-scale studies. The Molecular Registry of Pituitary Adenomas (REMAH) was promoted by the Andalusian Society of Endocrinology and Nutrition (SAEN) in 2008 as a cooperative clinical-basic multicenter strategy aimed at improving diagnosis and treatment of pituitary adenomas by combining clinical, pathological, and molecular information. In 2010, the Spanish Society of Endocrinology and Nutrition (SEEN) extended this project to national level and established 6 nodes with common protocols and methods for sample and clinical data collection, molecular analysis, and data recording in a common registry (www.remahnacional.com). The registry combines clinical data with molecular phenotyping of the resected pituitary adenoma using quantitative real-time PCR of expression of 26 genes: Pituitary hormones (GH-PRL-LH-FSH-PRL-ACTH-CGA), receptors (somatostatin, dopamine, GHRH, GnRH, CRH, arginine-vasopressin, ghrelin), other markers (Ki67, PTTG1), and control genes. Until 2015, molecular information has been collected from 704 adenomas, out of 1179 patients registered. This strategy allows for comparative and relational analysis between the molecular profile of the different types of adenoma and the clinical phenotype of patients, which may provide a better understanding of the condition and potentially help in treatment selection. The REMAH is therefore a unique multicenter, interdisciplinary network founded on a shared database that provides a far-reaching translational approach for management of pituitary adenomas, and paves the way for the conduct of combined clinical-basic innovative studies on large patient samples.
KW - Acromegaly
KW - Cushing
KW - Multicenter study
KW - Pituitary adenoma
KW - Tumor
U2 - 10.1016/j.endonu.2016.03.001
DO - 10.1016/j.endonu.2016.03.001
M3 - Article
SN - 2530-0164
VL - 63
SP - 274
EP - 284
JO - Endocrinologia, Diabetes y Nutricion
JF - Endocrinologia, Diabetes y Nutricion
IS - 6
ER -